Articles
Pembrolizumab plus pomalidomide and dexamethasone
for patients with relapsed or refractory multiple myeloma
(KEYNOTE-183): a randomised, open-label, phase 3 trial
Maria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, Albert Oriol, David Simpson, Anupkumar George, Hartmut Goldschmidt,
Alessandra Larocca, Asher Chanan-Khan, Daniel Sherbenou, Irit Avivi, Noam Benyamini, Shinsuke Iida, Morio Matsumoto, Kenshi Suzuki,
Vincent Ribrag, Saad Z Usmani, Sundar Jagannath, Enrique M Ocio, Paula Rodriguez-Otero, Jesus San Miguel, Uma Kher, Mohammed Farooqui,
Jason Liao, Patricia Marinello, Sagar Lonial, for the KEYNOTE-183 Investigators*
Summary
Background Pomalidomide and dexamethasone is a standard of care for patients with multiple myeloma in whom Lancet Haematol 2019
bortezomib and lenalidomide treatment has failed. KEYNOTE-183 assessed efficacy and safety of pomalidomide Published Online
and dexamethasone with or without pembrolizumab in patients with relapsed or refractory multiple myeloma. July 18, 2019
Here, we present the findings of an unplanned, ad-hoc interim analysis at the request of the US Food and Drug http://dx.doi.org/10.1016/
S2352-3026(19)30110-3
Administration (FDA).
See Online/Comment
http://dx.doi.org/10.1016/
Methods KEYNOTE-183 was a randomised, open-label, phase 3 trial done at 97 medical centres across 11 countries S2352-3026(19)30149-8
(Australia, Canada, France, Germany, Israel, Italy, Japan, New Zealand, Norway, Spain, and USA). Patients aged at
*A complete list of investigators
least 18 years with multiple myeloma, an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, in the KEYNOTE-183 study is
previously treated with at least two lines of therapy (excluding pomalidomide) and refractory to the last line were shown in appendix 1 (pp 1–2)
randomly assigned 1:1 to the pembrolizumab plus pomalidomide and dexamethasone group or the pomalidomide Complejo Asistencial
and dexamethasone group via an interactive voice response or integrated web response system. Patients received oral Universitario de
Salamanca/IBSAL, Salamanca,
pomalidomide 4 mg daily on days 1–21 and oral low-dose dexamethasone 40 mg on days 1, 8, 15, and 22 in 28-day
Spain (M-V Mateos MD);
cycles, with or without intravenous pembrolizumab 200 mg every 3 weeks. The dual primary endpoints were Middlemore Hospital,
progression-free survival and overall survival. Efficacy was assessed in all randomly assigned patients and safety was Auckland, New Zealand
(H Blacklock MBChB); Oslo
assessed in patients who received at least one dose of study treatment. The trial is registered at ClinicalTrials.gov,
Myeloma Center, Oslo
number NCT02576977, and it is closed for accrual.
University Hospital and KG
Jebsen Center for B-Cell
Findings Between Jan 18, 2016, and June 7, 2017, 249 patients were randomly assigned to either the pembrolizumab Malignancies, University
of Oslo, Oslo, Norway
plus pomalidomide and dexamethasone group (n=125) or the pomalidomide and dexamethasone group (n=124). On
(F Schjesvold MD); Institut
July 3, 2017, the FDA established that risks associated with the triple combination outweighed benefits and halted the
Català d’Oncologia and Institut
study. Median follow-up was 8·1 months (IQR 4·5–10·9). Median progression-free survival was 5·6 months (95% CI Josep Carreras, Hospital
3·7–7·5) in the pembrolizumab plus pomalidomide and dexamethasone group versus 8·4 months (5·9–not reached) Germans Triasi Pujol,
Barcelona, Spain (A Oriol MD);
in the pomalidomide and dexamethasone group; progression-free survival estimates at 6 months were 48% (95% CI
North Shore Hospital,
37–58) versus 60% (49–69) at 6 months (hazard ratio [HR] 1·53; 95% CI 1·05–2·22; p=0·98). Median overall survival Auckland, New Zealand
was not reached (95% CI 12·9–not reached) versus 15·2 months (12·7–not reached; HR 1·61; 95% CI 0·91–2·85; (D Simpson MD); Wellington
p=0·95); overall survival estimates at 6 months were 82% (95% CI 74–88) versus 90% (82–95). Serious adverse events Blood and Cancer Center,
Wellington, New Zealand
occurred in 75 (63%) of 120 patients in the pembrolizumab plus pomalidomide and dexamethasone group versus
(A George MD); University
56 (46%) of 121 patients in the pomalidomide and dexamethasone group. Four (3%) treatment-related deaths occurred Hospital Heidelberg and
in the pembrolizumab plus pomalidomide and dexamethasone group (one each of unknown cause, neutropenic National Center of Tumor
sepsis, myocarditis, and Stevens–Johnson syndrome); myocarditis and Stevens-Johnson syndrome were considered Diseases in Heidelberg,
Heidelberg, Germany
related to pembrolizumab. No treatment-related deaths were reported in the pomalidomide and dexamethasone
(H Goldschmidt MD); Myeloma
group. Unit, Division of Hematology,
University of Torino, Azienda
Interpretation The results from this unplanned, FDA-requested, interim analysis showed that the benefit–risk profile Ospedaliero-Universitaria Città
della Salute e della Scienza di
of pembrolizumab plus pomalidomide and dexamethasone is unfavourable for patients with relapsed or refractory
Torino, Torino, Italy
multiple myeloma. (A Larocca MD); Mayo Clinic,
Jacksonville, FL, USA
Funding Merck Sharp & Dohme, a subsidiary of Merck & Co (Kenilworth, NJ, USA). (A Chanan-Khan MD);
University of Colorado Cancer
Center, Denver, CO, USA
Copyright © 2019 Elsevier Ltd. All rights reserved. (D Sherbenou MD); Sourasky
Medical Center, Haifa, Israel
Introduction and immunodeficiency, accounts for about 1% of all (I Avivi MD); Rambam Health
Care Campus, HaAliya
Multiple myeloma, a malignant disorder of clonal plasma cancers and 10% of haematological cancers.1,2
HaShniya, Israel
cells characterised by osteolytic bone lesions, renal disease, Immunomodulatory imide drugs lenalidomide and (N Benyamini MD); Nagoya City
www.thelancet.com/haematology Published online July 18, 2019 http://dx.doi.org/10.1016/S2352-3026(19)30110-3 1
Articles
University Graduate School of
Medical Sciences, Mizuho-cho, Research in context
Mizuho-ku, Nagoya, Japan
Evidence before this study progression-free survival of 17·4 months [95% CI 11·7–18·8])
(S Iida MD); National Hospital
Organization, Shibukawa We did a PubMed search using the terms “relapsed” and with the combination of pembrolizumab and pomalidomide
Medical Center, Shibukawa, “multiple myeloma” filtered by article type (clinical trial) and and dexamethasone in patients with relapsed or refractory
Gunma, Japan
publication dates (Jan 1, 2013, to Nov 27, 2018) with no multiple myeloma. A phase 1b study showed acceptable safety
(M Matsumoto MD); Japanese
Red Cross, Tokyo, Japan language restrictions, which yielded 70 articles. Treatment of (drug-related adverse events in 63% of patients) and
(K Suzuki MD); Institut Gustave relapsed or refractory multiple myeloma poses the unique antitumour activity (complete response after radiotherapy in
Roussy, Villejuif, France challenge of balancing efficacy and safety in patients who tend one [4%] of 27 patients) with nivolumab in patients with
(V Ribrag MD); Levine Cancer
to have had many previous treatments and are older. Therefore, relapsed or refractory multiple myeloma. These results provide
Institute/Atrium Health,
Charlotte, NC, USA several ongoing phase 1 and 2 trials are being done to assess a promising backdrop for the KEYNOTE-183 study.
(S Z Usmani MD); The Mount combinations of the following drugs: bendamustine,
Added value of this study
Sinai Medical Hospital, tivantinib, bortezomib, carfilzomib, ixazomib, delanzomib,
New York, NY, USA This phase 3 study was done to assess the efficacy and safety of
venetoclax, ricolinostat, vorinostat, lenalidomide,
(S Jagannath MD); Hospital the checkpoint inhibitor pembrolizumab with pomalidomide
Universitario Marqués de pomalidomide, daratumumab, isatuximab, elotuzumab and
and dexamethasone in patients with relapsed or refractory
Valdecilla (IDIVAL), Universidad pembrolizumab. The phase 2 ELOQUENT-3 study in patients
multiple myeloma. Despite positive results in a previous study,
de Cantabria, Santander, Spain with relapsed or refractory multiple myeloma showed
(E M Ocio MD); Clinica an interim analysis done at a median follow-up of 8·1 months
improved progression-free survival in patients treated with
Universidad de Navarra, CIMA, (IQR 4·5–10·9) at the request of the US FDA showed an
IDISNA, CIBERONC, Pamplona, immunostimulatory antibody against SLAMF7 (elotuzumab)
unfavourable benefit–risk profile for the pembrolizumab plus
Spain (P Rodriguez-Otero MD, plus pomalidomide and dexamethasone versus pomalidomide
pomalidomide and dexamethasone combination in patients
J San Miguel MD); Merck & Co, and dexamethasone alone (10·3 months vs 4·7 months; hazard
Kenilworth, NJ, USA (U Kher MS, with relapsed or refractory multiple myeloma and
ratio 0·54; p=0·008). This result led to the recent US Food and
M Farooqui DO, J Liao PhD, KEYNOTE-183 was halted.
P Marinello PharmD); and Drug Administration (FDA) approval of the elotuzumab
Winship Cancer Institute, combination in relapsed or refractory multiple myeloma. Implications of all the available evidence
Emory University, Atlanta, GA, Narrowing the search by adding filters for the terms “multiple Although the results of KEYNOTE-183 are unlikely to change
USA (S Lonial MD)
myeloma” and “PD-1” yielded only two results relevant to clinical practice in light of alternative, efficacious, and safe triplet
Correspondence to:
Dr María-Victoria Mateos, relapsed or refractory multiple myeloma, both involving a PD-1 and quadruplet treatments in this setting, this study might
University Hospital of inhibitor. One phase 2, single-arm trial reported acceptable provide valuable information to guide the design of future
Salamanca-Instituto de safety (grade 3 or 4 adverse events in 40% of patients) and clinical studies involving checkpoint inhibitors in relapsed or
Investigacion Biomedica de promising activity (response in 60% of patients and median refractory multiple myeloma.
Salamanca, 37007 Salamanca,
Spain
mvmateos@usal.es
pomalidomide, proteasome inhibitors such as bortezomib In the KEYNOTE-183 study, we assessed clinical effects
and carfilzomib, and effective combination with novel of combining pembrolizumab with pomalidomide and
therapies with different mechanisms of action such as dexamethasone in patients with relapsed or refractory
daratumumab have improved overall survival in multiple multiple myeloma. We present the results of the
myeloma.3–9 Most patients still undergo cycles of remission unplanned, interim efficacy (survival outcomes and
and relapse until the disease becomes refractory. Prognosis tumour response) and safety analyses.
is poor in patients who are refractory to immunomodulatory
imides or proteasome inhibitors.10 Effective combination Methods
of novel therapies with different mechanisms of action Study design and participants
remains an unmet need. KEYNOTE-183 was a randomised, open-label, phase 3
Pembrolizumab is a highly selective humanised mono- trial of pembrolizumab plus pomalidomide and
clonal antibody against PD-1 that blocks interaction between dexamethasone compared with pomalidomide and
PD-1 and its ligands PD-L1 and PD-L2, with antitumour dexamethasone alone in patients with relapsed or
activity across multiple tumour types.11–14 In two phase 1 refractory multiple myeloma. Patients were enrolled at
studies, pembrolizumab as monotherapy and in combin- 97 medical centres across 11 countries (Australia,
ation with lenalidomide and low-dose dexamethasone had Canada, France, Germany, Israel, Italy, Japan,
manageable safety and promising antitumour activity in New Zealand, Norway, Spain, and USA). The trial
See Online for appendix 2 patients with relapsed or refractory multiple myeloma.15,16 In protocol is available in appendix 2 (pp 1–151). The study
a phase 2 study, pembrolizumab plus pomalidomide and was done in accordance with the protocol and amend-
dexamethasone led to a response in 60% of patients, a ments, Good Clinical Practice Guidelines, and the
median response duration of 14·7 months (95% CI 7·9– Declaration of Helsinki. The protocol and subsequent
17·5), and manageable safety, supporting a randomised trial amendments were approved by the appropriate
of pembrolizumab-based therapy in patients with relapsed institutional review board or ethics committee at each
or refractory multiple myeloma.17 participating institution.
2 www.thelancet.com/haematology Published online July 18, 2019 http://dx.doi.org/10.1016/S2352-3026(19)30110-3
Articles
Eligibility criteria were age 18 years or older; confirmed response system (randomised allocation schedules were
diagnosis of active multiple myeloma and measurable generated by the funder and provided to site staff as
disease; at least two previous lines of anti-myeloma required via an automated telephone system). Rando-
therapy, including immunomodulatory imides (lenali- misation was stratified by number of previous lines of
domide or thalidomide) and proteasome inhibitors therapy (two vs ≥three) and disease status (lenalidomide
(bortezomib, ixazomib, or carfilzomib); failure of last refractory vs sensitive). This was an open-label study;
line of therapy, defined as refractory (resistant to therefore, masking was not performed.
treatment or documented progression during or within
60 days of completing immunomodulatory imide or Procedures
proteasome inhibitor-based treatment) or relapsed and Patients received oral pomalidomide 4 mg daily on
refractory (relapse within 6 months of stopping treat- days 1–21 and oral low-dose dexamethasone 40 mg (20 mg
ment with an immunomodulatory imide or proteasome for patients aged >75 years) on days 1, 8, 15, and 22 in
inhibitor-containing regimen); Eastern Cooperative 28-day cycles, with or without intravenous pembrolizumab
Oncology Group (ECOG) performance status 0 or 1; 200 mg every 3 weeks. Dose interruptions were permitted
adequate organ (protocol-defined haemat ological, renal, in cases of medical or surgical events or for logistical
hepatic, and coagulation) function; and provision of reasons unrelated to study therapy; patients continued
bone marrow biopsy sample or aspirate material for with study therapy within 28 days of the scheduled
disease assessment and biomarker analysis. Patients interruption. Dose modification occurred per prespecified
were ineligible if they had non-secretory or oligosecretory protocol guidance for each of the treatment drugs in
myeloma; smouldering multiple myeloma; monoclonal response to toxicity (details in the redacted protocol).
gammopathy of unknown significance; plasma cell Treatment was continued until confirmed progression,
leukaemia; Waldenström’s macroglobulinaemia; hyper- unacceptable toxicity, or physician or patient decision to
sensitivity to thalidomide, lenalidomide, or dexa metha- withdraw.
sone; previous therapy with pomalidomide; active Disease response was assessed every 4 weeks; patients
autoimmune disease necessitating systemic treatment were considered non-evaluable if they had received at
in the past 2 years; evidence of active, non-infectious least one dose of study treatment but had not had post-
pneumonitis; active infection requiring intravenous treatment assessment or if they had been assigned to a
systemic therapy; known psychiatric or substance abuse group but had not received study treatment. Patients who
disorders that would interfere with compliance with discontinued for reasons other than progression had
trial requirements; history of repeated infections, post-treatment follow-up visits for disease status every
primary amyloidosis, hyperviscosity, or POEMS syn- 4 weeks until progression, initiation of non-study cancer
drome; history of immune suppression or is receiving treatment, withdrawal of consent, or loss to follow-up.
systemic steroid or immunosuppressive therapy within Patients were contacted for assessment of survival status
7 days of first dose of study drug; previous monoclonal every 12 weeks after the end of treatment.
antibody within 4 weeks of study or ongoing adverse Adverse events were graded per Common Terminology
events due to drugs administered more than 4 weeks Criteria for Adverse Events, version 4.0, and monitored
earlier; previous antimyeloma therapy within 2 weeks of throughout treatment and for 30 days (90 days for serious
study; previous allogeneic haemopoietic stem cell adverse events) after treatment end. Immune-mediated
transplantation (SCT) in 5 years before the study; adverse events were defined as adverse events—specified
autologous SCT in the 12 weeks before the study; by the sponsor (non-serious and serious) and included
plasmapheresis in the 4 weeks before the study; inability by the investigator—associated with pembrolizumab
to undergo thrombo embolic prophylaxis; peripheral exposure that were consistent with immune phenomena
neuropathy grade 2 or worse; another malignancy in the and had a potentially immunological cause regardless of
5 years before the study; previous therapy with an anti- attribution to study treatment or immune relatedness.
PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti- Attribution of adverse events to the study drugs was
cytotoxic T-lymphocyte-associated antigen-4 antibody; determined by site investigators.
HIV, hepatitis B, or hepatitis C infection; received live Patients could withdraw consent at any time for any
vaccine in 30 days before first dose of study drug; or if reason or be excluded from the trial at the investigator’s
they had an immediate relative who is investigational discretion in the event of untoward effects. Patients could
site or funder staff involved in this trial. All patients also have been withdrawn for the following reasons:
provided written informed consent to participate. documented disease progression, unacceptable adverse
events, intercurrent illness preventing further study
Randomisation and masking treatment, confirmed pregnancy, receipt of non-protocol-
Patients were randomly assigned 1:1 to the pembro- specified anti-myeloma therapy before documented
lizumab plus pomalidomide and dexamethasone group disease progression, non-adherence to trial treatment or
or the pomalidomide and dexamethasone group using procedures, loss to follow-up, and administrative reasons.
an interactive voice response system or integrated web The trial was to be terminated prematurely if quality or
www.thelancet.com/haematology Published online July 18, 2019 http://dx.doi.org/10.1016/S2352-3026(19)30110-3 3
Articles
quantity of data recording were inaccurate or incomplete, patients, the study had 88·7% power to show
adherence to the protocol and regulatory requirements a 25% difference between the groups (55% for pem-
were poor, plans were made to modify or discontinue brolizumab plus pomalidomide and dexamethasone vs
development of pembrolizumab, or in response to a 30% pomalidomide and dexamethasone) at a one-sided α
request by the US Food and Drug Administration (FDA) of 0·5%.
or other health authority because of safety concerns. Progression-free survival was compared between
treatment groups using a stratified log-rank test with a
Outcomes stratified Cox regression providing the HR. Proportions
The dual primary endpoints were progression-free of progression events were estimated within treatment
survival, defined as time from randomisation to first groups using the Kaplan-Meier method. Duration of
documented disease progression or death from any response was assessed descriptively using Kaplan-Meier
cause per International Myeloma Working Group 2011 statistics. Safety was analysed using descriptive statistics
criteria18 by masked independent central review, and overall and a tiered approach. There were no tier 1 events
overall survival, defined as time from randomisation to (subject to inferential testing for statistical significance
death from any cause. Secondary efficacy endpoints were between groups); tier 2 events, which must occur in at
overall response, duration of response, disease control, least four patients in any treatment group, were assessed
safety and tolerability of both treatments, and secondary using point estimates with 95% CIs for between-group
progression-free survival (time from randomisation to comparisons; tier 3 events (adverse events that are
subsequent disease progression after initiation of new neither tier 1 nor tier 2) were analysed using point
anticancer therapy or death from any cause, whichever estimates only. Immune-mediated adverse events were
occurs first, based on investigator assessment; not summarised separately by toxicity and grade (including
reported here). Overall response was the proportion of counts, percentages, and 95% CIs). Two interim analyses
patients who achieved at least a partial response, assessed were protocol-specified before final analysis: a final
by masked central review.19,20 Duration of response was analysis of objective response and a final progression-
defined as the time from first documented partial free survival analysis and interim overall survival analysis
response until progression or death, assessed by masked (appendix 2 p 104). Statistical analyses were done using
central review. Disease control was the proportion of SAS software, version 9.4.
patients with confirmed complete response, very good Efficacy was assessed in the intention-to-treat population
partial response, partial response, minimal response, or of all patients assigned to a treatment group. Safety was
stable disease for at least 12 weeks before confirmed assessed in patients who received at least one dose of
progression. The International Response Criteria for study treatment (safety population). An external data
multiple myeloma19 were used to define complete, very monitoring committee assessed safety and efficacy at
good partial, and partial responses, and stable and interim timepoints and made recommendations
progressive disease. Full description of these criteria is in regarding patient safety and study integrity. This trial is
appendix 1 (p 4). Median time to progression, defined as registered at ClinicalTrials.gov, number NCT02576977.
time from randomisation to first documented
progression, was also assessed. Role of the funding source
The funder of the study was involved in study design,
Statistical analysis data analysis, data interpretation, and writing of the
Hypothesis testing of objective response rate, progression- report, but not data collection. All authors had full access
free survival, and overall survival was controlled by a to all the data in the study and had final responsibility for
family-wise type I error rate of 2·5% (one-sided α).21 A the decision to submit for publication.
sample size of 300 patients was planned. For progression-
free survival, based on 236 events (estimated to occur Results
about 20 months after the first patient enrolled), the study Between Jan 18, 2016, and June 7, 2017, 348 patients were
had 90·6% power to detect a hazard ratio (HR) of 0·635 screened, of whom 97 were not eligible and two were not
with pembrolizumab plus pomalidomide and dexametha- assigned to a group before the study was halted, and
sone versus pomalidomide and dexamethasone (assuming 249 were randomly assigned to either the pembrolizumab
median progression-free survival of 4·0 months) at a plus pomalidomide and dexamethasone group (n=125) or
one-sided α of 1·5%. For overall survival, based on the pomalidomide and dexamethasone group (n=124). Of
182 events (estimated to occur 10 months after progression- these, 120 patients in the pembrolizumab plus
free survival analysis), the study had 80·5% power to pomalidomide and dexamethasone group and 121 in the
detect a HR of 0·6 for pembrolizumab plus pomalidomide pomalidomide and dexamethasone group were treated
and dexamethasone versus poma lidomide and (figure 1). Dexamethasone 20 mg was given from the start
dexamethasone (assuming a median overall survival of of treatment in 81 patients (37 in the pembrolizumab plus
12·7 months) at a one-sided α of 0·5%. For overall pomalidomide and dexamethasone group and 44 in the
response, based on the first 210 randomly assigned pomalidomide and dexamethasone group). A list of key
4 www.thelancet.com/haematology Published online July 18, 2019 http://dx.doi.org/10.1016/S2352-3026(19)30110-3
Articles
changes made to the protocol after the start of the study is
in appendix 1 (p 3). On July 3, 2017, the FDA halted 348 patients screened
KEYNOTE-183 on the basis of interim data presented to
the data monitoring committee, which indicated that the
97 not eligible*
risks associated with the pembrolizumab combination
31 did not receive at least two previous therapies or
outweighed the benefits.22 Pembrolizumab was treatment with an immunomodulatory imide drug
immediately discontinued after the FDA decision to halt 30 had inadequate organ function
14 received prohibited previous therapies
the trial and patients were transferred to available 12 had no confirmed diagnosis of multiple myeloma or
standard-of-care therapies at their physician’s discretion measurable disease
11 did not provide consent
and according to local institutional regulations. Patient-
10 had ECOG performance status greater than 1
reported outcomes, pharmacokinetic endpoints, and 2 not randomly assigned to a group before study was
halted
exploratory biomarker endpoints were not analysed and
the two preplanned interim analyses were not done
because of early trial termination. 249 randomly assigned
Baseline patient and disease characteristics were
generally similar between groups (table 1). More patients
in the pembrolizumab group had high-risk cytogenetics
than in the pomalidomide and dexa-m ethasone group 125 randomly assigned to receive 124 randomly assigned to receive
pembrolizumab, pomalidomide, pomalidomide and
(28 [22%] of 125 in the pembrolizumab group vs 17 [14%] and dexamethasone dexamethasone
of 124 in the pomalidomide and dexamethasone group),
including del17p13 (15 [12%] of 125 vs six [5%] of 124) and
5 did not receive study treatment 3 did not receive study treatment
plasmacytoma (15 (12%) of 125 [six extramedullary] vs
six [5%] of 124 [three extramedullary]; table 1). At the time
of the unplanned interim analysis, median follow-up was 120 received assigned treatment 121 received assigned treatment
8·1 months (IQR 4·5–10·9) across both groups and
7·8 months (IQR 4·0–10·5) in the pembrolizumab group
80 discontinued treatment 68 discontinued treatment
versus 8·6 months (IQR 5·1–11·1) in the pomalidomide
46 progressive disease 41 progressive disease
and dexa methasone group (appendix 1 p 5). At data 22 adverse events 9 adverse events
cutoff, 40 (33%) of the 120 patients who started treatment 7 physician decision 8 physician decision
4 patient decision 9 patient decision
in the pembrolizumab group versus 53 (44%) of the 1 withdrawal 1 withdrawal
121 who started treatment in the pomalidomide and
dexamethasone group were still on study treatment;
Study terminated by FDA Study terminated by FDA
80 (67%) patients versus 68 (56%) had discontinued
40 had ongoing treatment and 53 had ongoing treatment and
(figure 1). Disease progression was the most common entered the safety or survival entered the safety or survival
reason for study discontinuation in both treatment follow-up follow-up
groups (46 [38%] patients in the pembrolizumab group vs
Figure 1: Trial profile
41 [34%] patients in the pomalidomide and
ECOG=Eastern Cooperative Oncology Group. FDA=Food and Drug Administration. *Reasons are not
dexamethasone group), followed by adverse events exclusive—ie, one patients can meet more than one criteria.
(22 [18%] vs nine [7%]). 18 (15%) patients in the
pembrolizumab group and five (4%) in the pomalidomide reached) in the pomalidomide and dexamethasone
and dexamethasone group discontinued because of group. Estimated progression-free survival was 48%
treatment-related adverse events. (95% CI 37–58) versus 60% (49–69) at 6 months and
Because of premature study termination, progression- 68% (58–76) versus 79% (70–85) at 3 months (figure 2A).
free survival and response endpoints were assessed by Median overall survival was not reached (95% CI
substantiated investigator assessment. At database cutoff 12·9–not reached) in the pembrolizumab group versus
(June 2, 2017), median progression-free survival was 15·2 months (12·7–not reached) in the pomalidomide
5·6 months (95% CI 3·7–7·5) in the pembrolizumab and dexamethasone group; the HR for death was 1·61
plus pomalidomide and dexamethasone group versus (95% CI 0·91–2·85; p=0·95). Estimated overall survival
8·4 months (5·9–not reached) in the pomalidomide and was 82% (95% CI 74–88) versus 90% (82–95) at 6 months
dexamethasone group; with an HR for disease and 90% (83–95) versus 98% (93–100) at 3 months
progression or death of 1·53 (95% CI 1·05–2·22; p=0·98; (figure 2B). The HR for comparison of overall survival
figure 2A). The number of progression-free survival was similar among subgroups, except for ECOG
events was 115 (65 [52%] patients in the pembrolizumab performance status 0, disease stages 1 and 2, and patients
group and 50 [40%] in the pomalidomide and dexa- from Japan (appendix 1 p 19). The HR for comparison of
methasone group). Median time to progression was progression-free survival was similar among subgroups,
8·1 months (95% CI 5·6–not reached) in the except for the race (other) and Japan subgroups
pembrolizumab group versus 8·7 months (6·6–not (appendix 1 p 20).
www.thelancet.com/haematology Published online July 18, 2019 http://dx.doi.org/10.1016/S2352-3026(19)30110-3 5
Articles
43 (34%; 95% CI 26·1–43·4) of 125 patients in the
Pembrolizumab plus Pomalidomide and
pembrolizumab group achieved an overall response
pomalidomide and dexamethasone
dexamethasone group(n=124) (partial response or better) compared with 50 (40%;
group (n=125) 31·6–49·5) of 124 in the pomalidomide and dexa-
Age, years 65 (60–72) 67 (60–74) methasone group (appendix 1 p 6). Disease control was
70–79 years 37 (30%) 38 (31%) achieved by 106 (85%; 77·3–90·6) patients in the
≥80 years 7 (6%) 10 (8%) pembrolizumab group and 105 (85%; 77·1–90·5) in the
pomalidomide and dexamethasone group. Median
Sex
duration of response was 8·2 months (95% CI 5·2–not
Female 48 (38%) 46 (37%)
reached) in the pembrolizumab group and was not
Male 77 (62%) 78 (63%)
reached in the pomalidomide and dexamethasone group
ECOG performance status
(appendix 1 p 5).
0 60 (48%) 60 (48%)
Median duration of study treatment was 123·5 days
1 65 (52%) 64 (52%)
(IQR 57·5–225·0) in the pembrolizumab group and
International Staging System stage
127·0 days (78·0–253·0) in the pomalidomide and
I 45 (36%) 45 (36%)
dexamethasone group (appendix 1 p 6); at analysis,
II 46 (37%) 39 (31%)
patients had received a median of 4·4 cycles (2·0–9·0) of
III 33 (26%) 33 (27%)
treatment.
Missing 1 (1%) 7 (6%)
Adverse events of any grade were reported in 119 (99%)
Number of previous 3 (1–3) 3 (1–3)
of 120 patients in the pembrolizumab group versus
recurrences
116 (96%) of 121 in the pomalidomide and dexamethasone
Cytogenetics*
group; grade 3 or 4 adverse events were reported in
High-risk del17p13, 28 (22%) 17 (14%)
t(4;14), or t(14;16) 90 (75%) of 120 versus 77 (64%) of 121 patients; and
Del17p13 15 (12%) 6 (5%) serious adverse events were reported in 75 (63%) of 120
t(4;14) 10 (8%) 8 (6%) versus 56 (46%) of 121 patients (appendix 1 p 7). Grade 5
t(14;16) 8 (6%) 3 (2%) adverse events occurred in 13 (11%) patients in the
Normal 52 (42%) 71 (57%) pembrolizumab group versus three (2%) in the
pomalidomide and dexamethasone group (table 2). Any-
Missing 9 (7%) 7 (6%)
grade adverse events with an at least 5% difference in
Renal impairment† 8 (6%) 21 (17%)
incidence between groups were neutropenia, anaemia,
Presence of plasmacytoma‡ 15 (12%) 6 (5%)
fatigue, pneumonia, nausea, headache, back pain, and
Bone 9/15 (65%) 3/6 (50%)
increase in alanine aminotransferase (table 2). Grade 3 or
Extramedullary 6/15 (40%) 3/6 (50%)
4 adverse events with an at least 5% difference between
Previous autologous stem 77 (62%) 81 (65%)
cell transplantation groups were neutropenia (41 [34%] of 120 vs 26 [21%] of
Previous therapy 121) and thrombocytopenia (14 [12%] of 120 vs eight [7%]
Lenalidomide 119 (95%) 116 (94%) of 121). No serious adverse events occurred with at least a
5% difference between groups; serious adverse events
Thalidomide 48 (38%) 41 (33%)
with at least 3% difference between groups are in
Bortezomib 121 (97%) 116 (94%)
appendix 1 (p 7). Data regarding timing of onset of
Carfilzomib 34 (27%) 33 (27%)
adverse events are not available. Immune-mediated
Daratumumab 9 (7%) 8 (6%)
adverse events (most commonly pneumonitis,
Lenalidomide refractory 107 (86%) 107 (86%)
hyperthyroidism, and rash in 3% of patients each)
Refractory§
occurred in 21 (18%) of 120 patients in the pembrolizumab
Double 51 (41%) 50 (40%)
group (table 3). The minimum median time to onset of
Triple 23 (18%) 29 (23%)
any immune-mediated adverse event in patients who
Quadruple 5 (4%) 2 (2%)
received pembrolizumab was 10 days (severe skin
Data are median (IQR), n (%), or n/N (%). ECOG=Eastern Cooperative Oncology reaction), with an IQR of 14–65 across all immune-
Group. FISH=fluorescence in-situ hybridisation. *Baseline cytogenetics were
mediated adverse events. Only one patient had immune-
analysed in bone marrow aspirate sample by FISH or by standard karyotyping if
FISH was unavailable, at local laboratories. †Creatinine clearance less than mediated neutropenia, and there were no cases of
40 mL/min or serum creatinine more than 177 μmol/L (>2 mg/dL). ‡Presence of immune-mediated thrombocytopenia.
extramedullary soft tissue plasmacytoma was assessed by MRI, CT, or PET/CT at
Adverse events resulted in treatment discontinuation in
screening. §Patients were considered refractory if two (double; lenalidomide and
bortezomib), three (triple; lenalidomide, bortezomib, and pomalidomide or 24 (20%) of 120 patients in the pembrolizumab group
lenalidomide, bortezomib, and carfilzomib) or four (quadruple; lenalidomide, versus ten (8%) of 121 patients in the pomalidomide and
bortezomib, pomalidomide, and carfilzomib) previous lines of treatment were
dexamethasone group. The most common (occurring in
ineffective, defined as documented disease progression during or within 60 days
of completing their last anti-myeloma therapy. at least two patients in either group) were death (three [3%]
vs 0), pneumonia (two [2%] vs one [1%]), neutropenic
Table 1: Baseline characteristics of the intention-to-treat population
sepsis (two [2%] vs 0), cerebrovascular accident (two [2%]
6 www.thelancet.com/haematology Published online July 18, 2019 http://dx.doi.org/10.1016/S2352-3026(19)30110-3
Articles
vs one [1%]), and dyspnoea (two [2%] vs 0). Of these,
A
the cases of neutropenic sepsis, pneumonia, and
100
cerebrovascular accident were considered by the
90
investigator to be related to treatment. Treatment-related
80 adverse events resulted in treatment discontinuation in
18 (15%) patients in the pembrolizumab group and 70
five (4%) patients in the pomalidomide and dexamethasone 60
group; adverse events resulting in treatment interruption 50
occurred in 72 (60%) and 60 (50%) patients. 40
As of June 2, 2017, 50 patients had died: 29 (23%) of 30
125 in the pembrolizumab group (16 from progressive 20
disease and 13 from adverse events) versus 21 (17%) of 10
124 in the pomalidomide and dexamethasone group 0
(18 from progressive disease and three from adverse 0 2 4 6 8 10 12 14 16 18
Number at risk
events). Four (3%) of 120 patients died as a result of (number censored)
Pembrolizumab plus pomalidomide125 (0) 81 (15) 50 (13) 37 (8) 24 (12) 12 (7) 8 (11) 4 (3) 0 (2) 0 (0)
treatment-related adverse events in the pembrolizumab
and dexamethasone
group (one each of unknown cause, neutropenic sepsis, Pomalidomide and dexamethasone124 (0) 91 (9) 61 (11) 46 (11)29 (16) 17 (22) 5 (19) 2 (11) 0 (4) 0 (0)
myocarditis, and Stevens–Johnson syndrome; table 4).
Deaths from myocarditis and Stevens–Johnson syndrome
were attributed to pembrolizumab by the investigator.
Three non-treatment-related deaths occurred in the
pomalidomide and dexamethasone group (one each of
unknown cause, anaemia, and pneumonia; table 4). A
review of disease characteristics among patients who died
showed that more patients in the pembrolizumab group
than the pomalidomide and dexamethasone group had
International Staging System stage III disease (15 [52%] of
29 in the pembrolizumab group vs four [19%] of 21 in the
pomalidomide and dexamethasone group), high-risk
cytogenetics (ten [34%] vs six [29%]), plasmacytoma
(seven [24%] vs three [14%]), and ECOG performance
status of 1 (21 [72%] vs 13 [62%]) at baseline (appendix 1
p 8). The HR for death was 1·23 (95% CI 0·57–2·66;
p=0·69) when patients with these high-risk disease
characteristics were excluded (appendix 1 p 21). After
exclusion of patients with high-risk characteristics, of the
Figure 2: Progression-free survival by investigator assessment (A) and overall survival (B), in the intention-
13 deaths in the pembrolizumab group, four were from
to-treat population
progression and nine were from adverse events (one each
of myocardial infarction, cardiac failure, pericardial plasmacytoma, and double-refractory status were more
haemorrhage, and Stevens–Johnson syndrome, three relevant contributors to death than treatment (appendix 1
sepsis, and two unknown cause); two of these adverse p 22). Multivariable analysis showed that age, ECOG
events (Stevens–Johnson syndrome and unknown cause) performance status, and plasmacytoma significantly
were considered by the investigator to be related to contributed to the risk for death. ECOG performance
pembrolizumab. Of the 13 deaths in the pomalidomide status was both prognostic and predictive of outcome. An
and dexamethasone group after exclusion of patients with ECOG performance status of 0 was associated with
high-risk characteristics, 12 were from progression and reduced risk for death (HR 0·86; 95% Wald confidence
one was from an adverse event (unknown death). limits 0·32–2·29), whereas ECOG performance status 1
After study termination, a post-hoc analysis was done was associated with increased risk for death (HR 2·3;
to identify potential factors associated with the imbalance 95% Wald confidence limits 1·11–4·76). The clinical
in the number of deaths between the two treatment course of patients who died from adverse events in the
groups. Factors associated with being prognostic or pembrolizumab group is summarised in appendix 1
predictive of death were first assessed by retrospective (pp 9–18).
random forest analysis. A multivariable Cox regression
analysis was subsequently done to calculate differences Discussion
between groups with factors associated with risk for In this non-protocol-specified interim analysis of
death identified from the random forest analysis. Age, KEYNOTE-183, after a median follow-up of 8·1 months
ECOG performance status, disease stage, presence of (IQR 4·5–10·9), an increased risk for death was observed
www.thelancet.com/haematology Published online July 18, 2019 http://dx.doi.org/10.1016/S2352-3026(19)30110-3 7
)%(
lavivrus
eerf-noissergorP
B
100
90
80
70
60
50
40
30
20
10
0
0 2 4 6 8 10 12 14 16 18
Time since randomisation (months)
Number at risk
(number censored)
Pembrolizumab plus pomalidomide125 (0)105 (13) 91 (7) 73 (13) 53 (16) 37 (12) 18 (19) 7 (9) 1 (6) 0 (1)
and dexamethasone
Pomalidomide and dexamethasone124 (0)115 (9) 99 (11) 83 (11) 67 (16)42 (22)18 (19) 6 (11) 0 (4) 0 (0)
)%(
lavivrus
llarevO
Pembrolizumab plus pomalidomide,
and dexamethasone group
Pomalidomide and dexamethasone group
Hazard ratio 1·53 (95% CI 1·05–2·22), p=0·98
Hazard ratio 1·61 (95% CI 0·91–2·85), p=0·95
Articles
Pembrolizumab plus pomalidomide and Pomalidomide and dexamethasone group (n=121)
dexamethasone group (n=120)
Any Grades 1–2 Grade 3 Grade 4 Any Grades 1–2 Grade 3 Grade 4
Any 119 (99%) 19 (16%) 58 (48%) 32 (27%) 116 (96%) 37 (31%) 54 (45%) 23 (19%)
Neutropenia* 46 (38%) 5 (4%) 24 (20%) 17 (14%) 33 (27%) 7 (6%) 18 (15%) 8 (7%)
Anaemia* 34 (28%) 14 (12%) 20 (17%) 0 43 (36%) 27 (22%) 13 (11%) 3 (2%)
Fatigue* 29 (24%) 29 (24%) 0 0 36 (30%) 26 (21%) 9 (7%) 1 (1%)
Constipation 27 (23%) 26 (22%) 1 (1%) 0 24 (20%) 24 (20%) 0 0
Pyrexia 27 (23%) 26 (22%) 1 (1%) 0 23 (19%) 19 (16%) 1 (1%) 3 (2%)
Pneumonia* 28 (23%) 12 (10%) 15 (13%) 1 (1%) 18 (15%) 2 (2%) 14 (12%) 1 (1%)
Thrombocytopenia* 25 (21%) 11 (9%) 8 (7%) 6 (5%) 20 (17%) 12 (10%) 6 (5%) 2 (2%)
Diarrhoea 21 (18%) 19 (16%) 2 (2%) 0 21 (17%) 19 (16%) 2 (2%) 0
Upper respiratory tract infection 21 (18%) 17 (14%) 2 (2%) 1 (1%) 21 (17%) 19 (16%) 2 (2%) 0
Dyspnoea 21 (18%) 20 (17%) 1 (1%) 0 18 (15%) 15 (12%) 2 (2%) 1 (1%)
Nausea* 20 (17%) 20 (17%) 0 0 14 (12%) 13 (11%) 1 (1%) 0
Peripheral oedema 19 (16%) 19 (16%) 0 0 19 (16%) 18 (15%) 1 (1%)
Cough 18 (15%) 18 (15%) 0 0 18 (15%) 17 (14%) 1 (1%) 0
Neutrophil count decreased 17 (14%) 2 (2%) 9 (8%) 6 (5%) 16 (13%) 5 (4%) 6 (5%) 5 (4%)
Dizziness 15 (13%) 14 (12%) 1 (1%) 0 13 (11%) 13 (11%) 0 0
Headache* 15 (13%) 15 (13%) 0 0 5 (4%) 5 (4%) 0 0
Asthenia 14 (12%) 14 (12%) 0 0 14 (12%) 11 (9%) 3 (2%) 0
Back pain* 13 (11%) 13 (11%) 0 0 20 (17%) 15 (12%) 5 (4%) 0
Alanine aminotransferase increased* 12 (10%) 6 (5%) 6 (5%) 0 3 (2%) 1 (1%) 2 (2%) 0
White blood cell count decreased 12 (10%) 4 (3%) 8 (7%) 0 10 (8%) 6 (5%) 3 (2%) 1 (1%)
Muscle spasms 12 (10%) 12 (10%) 0 0 12 (10%) 12 (10%) 0 0
Data are n (%). 13 grade 5 events occurred in the pembrolizumab plus pomalidomide and dexamethasone group (three unknown cause and three sepsis and one each of
cardiac failure, myocardial infarction, myocarditis, pericardial hemorrhage, neutropenic sepsis, respiratory tract infection, and Stephens–Johnson syndrome) and three
occurred in the lenalidomide and dexamethasone group (one each of unknown cause, anaemia, and pneumonia). *Any-grade or grade 3 or 4 (combined) adverse events with
at least 5% difference between treatment groups.
Table 2: Adverse events occurring in at least 10% of patients in either treatment group in the safety population
with pembrolizumab plus pomalidomide and dexa-
Any Grades 1–2 Grades 3–4
methasone versus poma lidomide and dexamethasone
Any event 21 (18%) 11 (9%) 10 (8%) alone in patients with relapsed or refractory multiple
Pneumonitis 4 (3%) 3 (3%) 1 (1%) myeloma. The early mortality signal led to a halt of
Hyperthyroidism 3 (3%) 3 (3%) 0 enrolment by the data monitoring committee and to
Rash 3 (3%) 0 3 (3%) subsequent study termination by the FDA on July 3, 2017.22
Hypothyroidism 2 (2%) 2 (2%) 0 Early study termination resulted in incomplete data
Myopathy 2 (2%) 0 2 (2%) collection; at analysis, only 50 (27%) of the 182 protocol-
Myocarditis 1 (1%) 0 0 specified events required for analysis of overall survival
Iridocyclitis 1 (1%) 1 (1%) 0 and 115 (49%) of the 236 required for analysis of
Hepatitis 1 (1%) 0 1 (1%) progression-free survival had occurred. Treatment
Anaphylaxis 1 (1%) 1 (1%) 0 exposure was also shortened, with a median of
Infusion-related reactions 1 (1%) 1 (1%) 0 4·5 treatment cycles (IQR 2·0–8·0) in the pembrolizumab
Exfoliative dermatitis 1 (1%) 1 (1%) 0 plus pomalidomide and dexamethasone group (37 [31%]
Psoriasis 1 (1%) 1 (1%) 0 of 120 patients had fewer than three cycles) compared
Skin necrosis 1 (1%) 1 (1%) 0 with a median of 5·0 treatment cycles (3·0–9·0) in the
Stevens–Johnson syndrome 1 (1%) 0 0 pomalidomide and dexamethasone group (29 [24%] of
121 had fewer than three cycles). Longer follow-up
Data are n (%). Immune-mediated adverse events of clinical interest are presented. Two grade 5 immune-mediated
is necessary to discern efficacy outcomes with
events occurred (myocarditis and Stevens–Johnson syndrome).
immunotherapies given the non-proportional hazards
Table 3: Immune-mediated adverse events and infusion reactions with pembrolizumab plus
effect that leads to delayed clinical response and late
lenalidomide and dexamethasone (n=120) in the safety population
separation of Kaplan-Meier survival curves.23–25 As such,
although the overlapping CIs for progression-free survival
and overall response in this premature analysis suggest
8 www.thelancet.com/haematology Published online July 18, 2019 http://dx.doi.org/10.1016/S2352-3026(19)30110-3
Articles
no difference between the two treatment groups, this
Pembrolizumab Pomalidomide and
interpretation is limited by the early study termination.
plus pomalidomide dexamethasone
The acknowledged association between severity of and group (n=121)
disease and degree of immune system dysfunction26,27 dexamethasone
group (n=120)
suggests that PD-1 blockade is safer and more effective in
patients with lower burden of disease and less-impaired Any 13 (11%) 3 (2%)
immune systems. Therefore, the failure of pembro- Unknown cause‡ 3 (3%)* 1 (1%)
lizumab to improve the outcomes in patients with Sepsis 3 (3%) 0
relapsed or refractory multiple myeloma in our study Anaemia 0 1 (1%)
population might be attributable to the considerable Cardiac failure 1 (1%) 0
immunodeficiency that exists in these patients.28 Myocardial infarction 1 (1%) 0
The incidence of any-grade adverse events was similar Myocarditis 1 (1%)*† 0
between groups, although grade 3 or 4 and serious adverse Pericardial haemorrhage 1 (1%) 0
events occurred more frequently with pembrolizumab Neutropenic sepsis 1 (1%)* 0
plus pomalidomide and dexamethasone than with Pneumonia 0 1 (1%)
pomalidomide and dexamethasone. All common, non- Respiratory tract infection 1 (1%) 0
severe adverse events were manageable and no specific Stevens–Johnson syndrome 1 (1%)*† 0
type led to treatment discontinuation. The most common
immune-mediated adverse events were pneumonitis, Data are n (%). *Treatment related in one patient. †Attributed to pembrolizumab
by investigator. ‡Death and sudden death were combined as unknown-cause
hyperthyroidism, and rash (each in 3% of patients) in the
adverse events.
pembrolizumab plus pomalidomide and dexamethasone
Table 4: Adverse events leading to death in the safety population
group. Two grade 5 immune-mediated adverse events of
myo carditis and Stevens–Johnson syndrome occurred,
events expected per the label for pembrolizumab that group than in the pomalidomide and dexamethasone
were attributed to this drug.29 Overall, the type and group had stage III disease, high-risk cytogenetics, or
incidence of immune-mediated adverse events in the extramedullary plasmacytoma (three [43%] of seven vs
pembrolizumab plus pomalidomide and dexamethasone one [33%] of three), factors typically associated with poorer
group were consistent with those reported previously for prognosis; this imbalance might account for the difference
pembrolizumab11–14 and those observed in KEYNOTE-185.30 in early death that led to early termination of KEYNOTE-183.
More deaths occurred in the pembrolizumab plus Moreover, when adverse-event-related death was assessed
pomalidomide and dexamethasone group than in the between the two treatment groups, after removal of
pomalidomide and dexamethasone group. However, the patients with these high-risk characteristics, there was no
numbers of patients who discontinued or died from significant difference in numbers of deaths between
disease progression were similar between groups, groups. A multivariable analysis to identify factors
suggesting that the risk for progression was similar, associated with risk for death indicated that only ECOG
implying that progression-free survival in the performance status 1 was both predictive and prognostic of
pembrolizumab plus pomalidomide and dexamethasone risk for death. This might indicate that the performance
group could have been influenced by the imbalance in the status assessment of patients at study entry was under-
number of deaths, two of which were pembrolizumab estimated, considering patients with ECOG performance
related. Similarly, in the KEYNOTE-185 study30 of patients status of 2 are usually included in multiple myeloma
with newly diagnosed multiple myeloma, more deaths clinical studies but were not (per exclusion criteria) in this
occurred in the pembrolizumab plus lenalidomide and study. Together, these analyses suggest that the imbalance
dexamethasone group (19 [13%] of 149) than in the in the number of deaths is not only related to treatment
lenalidomide and dexamethasone group (nine [6%] (two deaths were pembrolizumab related) but also to non-
of 145). treatment-related adverse events.
The frequency of high-risk features at baseline among This study was limited by the ad-hoc unplanned nature
patients who died prematurely was higher in the of the analysis. The trial was terminated during the
pembrolizumab plus pomalidomide and dexamethasone enrolment period. Early termination also probably
group than in the pomalidomide and dexamethasone affected results of this unplanned analysis because of the
group, despite the safeguard of randomisation. Disease absence of longer-term follow-up efficacy data. The
characteristics were generally not balanced between the findings of this study are not generalisable to other
treatment groups in this study, probably because patient indications; it is not possible to establish whether the
enrolment was still ongoing at the time of early study problems encountered in the patients who received
termination and the unplanned ad-hoc nature of the pembrolizumab in combination with standard-of-care
analysis. Specifically, among the patients who died early therapy would be observed in other indications.
during the study, a greater proportion of those in the Our findings are disappointing given the positive
pembrolizumab plus pomalidomide and dexamethasone outcomes reported in the previous phase 2 study of
www.thelancet.com/haematology Published online July 18, 2019 http://dx.doi.org/10.1016/S2352-3026(19)30110-3 9
Articles
pembrolizumab plus pomalidomide and dexamethasone AstraZeneca; principal investigator or subinvestigator of clinical trials
in patients with relapsed or refractory multiple for Abbvie, Agios Pharmaceuticals, Amgen, Argen-X Bvba, Arno
myeloma.17 In the previous trial, the combination was Therapeutics, Astex Pharmaceuticals, AstraZeneca, Aveo, Bayer
Healthcare, Bbb Technologies, Blueprint Medicines, Boehringer
well tolerated and showed encouraging antimyeloma
Ingelheim, BMS, Celgene Corporation, Chugai Pharmaceutical, Clovis
activity, with a response achieved by 29 (60%) of 48 Oncology, Daiichi Sankyo, Debiopharm, Eisai, Eli Lilly, Exelixis, Forma,
patients and median progression-free survival of Gamamabs, Genentech, GlaxoSmithKline, H3 Biomedicine, Hoffmann
La Roche, Innate Pharma, Iris Servier, Janssen Cilag, Kyowa Kirin
17·4 months (95% CI 11·7–18·8);17 median follow-up was
Pharm Dev, Loxo Oncology, Lytix Biopharma, Medimmune, Menarini
longer than in our study.
Ricerche, MSD Chibret, Merrimack Pharmaceuticals, Merus,
Although these data showed an imbalance in the Millennium Pharmaceuticals, Nanobiotix, Nektar Therapeutics, Novartis
number of deaths between treatment groups, the interim Pharma, Octimet Oncology, Oncoethix, Onyx Therapeutics, Orion
Pharma, Oryzon Genomics, Pfizer, Pharma Mar, Pierre Fabre, Roche,
analyses were underpowered and inconclusive because
Sanofi Aventis, Taiho Pharma, Tesaro, and Xencor; and honoraria from
of the shortened follow-up at termination. Additional
Infinity Pharmaceuticals, BMS, Eisai, PharmaMar, and Gilead. SZU
studies are necessary to optimise identification of reports receiving consulting fees from Celgene, Millennium Takeda,
patients who would benefit from PD-1 inhibition in Onyx, and Sanofi; speaker’s fees from Celgene, Millennium Takeda, and
Onyx; and research funding from Array BioPharma, Celgene, Janssen
combination with pomalidomide. Furthermore, given
Oncology, Onyx, Pharmacyclics, and Sanofi. SJ reports receiving
the effectiveness of pembrolizumab combinations in the honoraria from Celgene and Karyopharm; and consulting fees from
treatment of other diseases, checkpoint inhibitors should Celgene, Janssen, Karyopharm, BMS, and Novartis. EMO reports
be appropriately investigated with other treatment receiving honoraria from Novartis, Takeda, AbbVie, PharmaMar, Seattle
Genetics, Amgen, Celgene, BMS, and Janssen; and research funding
backbones.
from Array Pharmaceuticals, Mundipharma, Celgene, Amgen, and
Contributors Sanofi. PR-O reports receiving consulting fees from Celgene, Janssen,
M-VM, JSM, UK, and PM contributed to study design or planning. HB, and Takeda; speaker’s fees from Celgene, BMS, and Janssen; and
IA, NB, SZU, SJ, JSM, UK, JL MF, PM, and SL contributed to data research funding from BMS and Celgene. JSM reports receiving
analysis. FS, AO, DSi, AG, HG, AL, AC-K, DSh, IA, NB, SI, MM, KS, consulting fees from Amgen, BMS, Celgene, Janssen, MSD, Novartis,
VR, EMO, PR-O, JSM, UK, MF, and PM contributed to acquisition of Takeda, Sanofi, and Roche. UK, MF, JL, and PM are employees of and
data. M-VM, HB, FS, AO, DSi, HG, AC-K, DSh, IA, SI, MM, VR, SZU, report stock ownership in Merck & Co, (Kenilworth, NJ, USA). SL
SJ, EMO, JSM, UK, MF, PM, and SL contributed to interpretation of the reports receiving consulting and advisory board fees from Amgen,
results. M-VM, HB, AO, KS, JSM, and PM contributed to drafting the Celgene, Novartis, BMS, Takeda, MSD, and Janssen; and research
manuscript. M-VM, FS, AO, DSi, AG, HG, AL, AC-K, DSh, IA, NB, SI, support from BMS, Janssen, Takeda, and Celgene. All other authors
MM, VR, SZU, SJ, EMO, PRO, JSM, UK, MF, JF, PM, and SL declare no competing interests.
contributed to critical review or revision of the article drafts.
Data sharing
All authors gave final approval for submission. All authors had access to
The data sharing policy of Merck Sharp & Dohme Corp, a subsidiary of
all the relevant study data and related analyses, vouch for the
Merck & Co, (Kenilworth, NJ, USA), including restrictions, is available
completeness and accuracy of the data and agree to be accountable for
For the MSD data sharing policy on the EngageZone website. Requests for access to the clinical study
all aspects of the work and will ensure that questions related to accuracy
see http://engagezone.msd.com/ data can be submitted through the EngageZone website or via email to
or integrity of any part of the work are appropriately investigated and
ds_documentation.php dataaccess@merck.com.
resolved, and have reviewed the final version of the manuscript to be
submitted and agree with the content and submission. Acknowledgments
Funding for this research was provided by Merck Sharp & Dohme Corp,
Declaration of interests
a subsidiary of Merck & Co, (Kenilworth, NJ, USA). Medical writing and
M-VM reports receiving consulting fees from Amgen, Celgene, Janssen,
editorial assistance were provided by Luana Atherly-Henderson, of
and Takeda. HB reports receiving consulting fees from Celgene and
Merck Sharp & Dohme Corp, and Matthew Grzywacz, of the ApotheCom
Janssen. FS reports receiving honoraria from Amgen, Celgene,
pembrolizumab team (Yardley, PA, USA). This assistance was funded by
Takeda, AbbVie, and Janssen; consulting fees from Adaptive, Pfizer,
Merck Sharp & Dohme Corp. We thank the patients and their families
Bristol-Myers Squibb (BMS), Amgen, Celgene, Takeda, and Bayer;
and caregivers, all primary investigators and their site personnel,
research funding from Amgen and Janssen; and reimbursements from
Bethanne Friedmann, Caryn Hampton, Yeliz Kiziltan, Deborah Wolfe,
Celgene and Amgen. AO reports receiving consulting fees from Amgen,
and Michelle Gallion (Merck & Co, Kenilworth, NJ, USA) for clinical
Janssen, and Takeda. DSi reports receiving honoraria from Merck Sharp
study support and Jonathan Cheng (Merck & Co, Kenilworth, NJ, USA)
& Dohme (MSD); honoraria and consulting fees from AbbVie, Celgene,
for critical review.
Janssen, and Roche; and research funding from Amgen. AG reports
receiving consulting fees and reimbursements from Celgene and Roche. References
HG reports receiving honoraria from Celgene, Janssen, Novartis, 1 Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC.
Chugai, BMS, and ArtTempi; consulting fees from Adaptive Multiple myeloma. Lancet 2009; 374: 324–39.
Biotechnology, Amgen, BMS, Celgene, Janssen, Sanofi, and Takeda; 2 Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A,
research funding from Amgen, BMS, Celgene, Chugai, Janssen, Sanofi, Flowers CR. 2016 US lymphoid malignancy statistics by World
Health Organization subtypes. CA Cancer J Clin 2016; 66: 443–59.
Takeda, Mundipharma, and Novartis; and reimbursements from
Amgen, BMS, Celgene, Janssen, Sanofi, and Takeda. AL reports 3 Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or
high-dose dexamethasone for relapsed multiple myeloma.
receiving honoraria from Amgen, BMS, Celgene, and Janssen; and has
N Engl J Med 2005; 352: 2487–98.
served on advisory boards for BMS, Celgene, Janssen, and Takeda. SI
4 Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on
reports receiving honoraria from Takeda, Ono, Janssen, Celgene, BMS,
overall survival from the MM-009 and MM-010 phase III trials of
and Novartis; and consulting fees from Takeda, Ono, Janssen, Sanofi,
lenalidomide plus dexamethasone in patients with relapsed or
and MSD. VR reports a consulting or advisory role for Infinity refractory multiple myeloma. Leukemia 2009; 23: 2147–52.
Pharmaceuticals, BMS, Gilead Sciences, NanoString Technologies,
5 San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus
Incyte, MSD, Roche/Genentech, Epizyme, immune design; research low-dose dexamethasone versus high-dose dexamethasone alone for
funding from arGEN-X BVBA; patents, royalties, and other intellectual patients with relapsed and refractory multiple myeloma (MM-003):
property regarding BAY1000394 studies; expert testimony for Servier; a randomised, open-label, phase 3 trial. Lancet Oncol 2013;
travel, accommodations, and expenses from Roche, BMS, and 14: 1055–66.
10 www.thelancet.com/haematology Published online July 18, 2019 http://dx.doi.org/10.1016/S2352-3026(19)30110-3
Articles
6 Jagannath S, Richardson PG, Barlogie B, et al. Bortezomib in 18 Rajkumar SV. Multiple myeloma: 2011 update on diagnosis,
combination with dexamethasone for the treatment of patients with risk-stratification, and management. Am J Hematol 2011; 86: 57–65.
relapsed and/or refractory multiple myeloma with less than optimal 19 Durie BGM, Harousseau JL, Miguel JS, et al. International uniform
response to bortezomib alone. Haematologica 2006; 91: 929–34. response criteria for multiple myeloma. Leukemia 2006; 20: 1467–73.
7 Paludo J, Mikhael JR, LaPlant BR, et al. Pomalidomide, bortezomib, 20 Kumar S, Paiva B, Anderson KC, et al. International Myeloma
and dexamethasone for patients with relapsed Working Group consensus criteria for response and minimal
lenalidomide-refractory multiple myeloma. Blood 2017; residual disease assessment in multiple myeloma. Lancet Oncol
130: 1198–204. 2016; 17: e328–46.
8 Shah JJ, Stadtmauer EA, Abonour R, et al. Carfilzomib, 21 Maurer W, Bretz F. Multiple testing in group sequential trials using
pomalidomide, and dexamethasone for relapsed or refractory graphical approaches. Stat Biopharm Res 2013; 5: 311–20.
myeloma. Blood 2015; 126: 2284–90. 22 The ASCO Post. FDA places clinical hold on three studies
9 Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus evaluating pembrolizumab in multiple myeloma. July 7, 2017.
pomalidomide and dexamethasone in relapsed and/or refractory http://www.ascopost.com/News/57813 (accessed May 1, 2019).
multiple myeloma. Blood 2017; 130: 974–81. 23 Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel
10 Kumar SK, Dimopoulos MA, Kastritis E, et al. Natural history of in advanced nonsquamous non-small-cell lung cancer. N Engl J Med
relapsed myeloma, refractory to immunomodulatory drugs and 2015; 373: 1627–39.
proteasome inhibitors: a multicenter IMWG study. Leukemia 2017; 24 Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus
31: 2443–48. docetaxel in patients with previously treated non-small-cell lung
11 Armand P, Shipp MA, Ribrag V, et al. Programmed death-1 cancer (OAK): a phase 3, open-label, multicentre randomised
blockade with pembrolizumab in patients with classical controlled trial. Lancet 2017; 389: 255–65.
Hodgkin lymphoma after brentuximab vedotin failure. 25 Chen TT. Statistical issues and challenges in immuno-oncology.
J Clin Oncol 2016; 34: 3733–39. J Immunother Cancer 2013; 1: 18.
12 Doi T, Piha-Paul SA, Jalal SI, et al. Safety and antitumor activity of 26 Markman JL, Shiao SL. Impact of the immune system and
the anti-programmed death-1 antibody pembrolizumab in patients immunotherapy in colorectal cancer. J Gastrointest Oncol 2015;
with advanced esophageal carcinoma. J Clin Oncol 2018; 36: 61–67. 6: 208–23.
13 Zinzani P, Thieblemont C, Melnichenko V, et al. Efficacy and safety 27 Janssen LME, Ramsay EE, Logsdon CD, Overwijk WW.
of pembrolizumab in relapsed/refractory primary mediastinal large The immune system in cancer metastasis: friend or foe?
B-cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE-170 J Immunother Cancer 2017; 5: 79.
phase 2 trial. Hematol Oncol 2017; 35: 62–63.
28 Guillerey C, Nakamura K, Vuckovic S, Hill GR, Smyth MJ.
14 Ribas A, Hamid O, Daud A, et al. Association of pembrolizumab Immune responses in multiple myeloma: role of the natural
with tumor response and survival among patients with advanced immune surveillance and potential of immunotherapies.
melanoma. JAMA 2016; 315: 1600–09. Cell Mol Life Sci 2016; 73: 1569–89.
15 Mateos MV, Orlowski RZ, Ocio EM, et al. Pembrolizumab 29 Merck Sharp & Dohme Corp. KEYTRUDA (pembrolizumab)
combined with lenalidomide and low-dose dexamethasone for for injection, for intravenous use. June, 2019. https://www.merck.
relapsed or refractory multiple myeloma: phase I KEYNOTE-023 com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf
study. Br J Haematol 2019; published online May 15. (accessed July 12, 2019).
DOI:10.1111/bjh.15946.
30 Usmani SZ, Schjesvold F, Oriol A, et al. Pembrolizumab plus
16 Ribrag V, Avigan DE, Green DJ, et al. Phase 1b trial of lenalidomide and dexamethasone for patients with treatment-naive
pembrolizumab monotherapy for relapsed/refractory multiple multiple myeloma (KEYNOTE-185): a randomised, open-label,
myeloma: KEYNOTE-013. Br J Haematol 2019; published online phase 3 trial. Lancet Haematol 2019; published online July 18.
April 1. DOI:10.1111/bjh.15888. http://dx.doi.org/10.1016/S2352-3026(19)30109-7.
17 Badros A, Hyjek E, Ma N, et al. Pembrolizumab, pomalidomide and
low dose dexamethasone for relapsed/refractory multiple myeloma.
Blood 2017; 130: 1189–97.
www.thelancet.com/haematology Published online July 18, 2019 http://dx.doi.org/10.1016/S2352-3026(19)30110-3 11
